STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial
关键词
抽象
描述
Post infarction heart failure (HF) remains a major cause of morbidity and mortality. In the United States, more than three million patients, and 700.000 in Italy, have cardiac failure and its most common cause is ischemic heart disease. The major goal to improve post infarction LV function would be the stimulation of neovascularization and the enhancement of regeneration of cardiac myocytes within the infarcted area. Recent experimental studies suggest that bone marrow-derived progenitor cells (BMCs) or circulating endothelial progenitor cells (cEPCs) contribute to the regeneration of infarcted myocardium, to enhance neovascularization of ischemic myocardium, to prevent cardiomyocyte apoptosis, to alter scar formation by reducing the development of myocardial fibrosis and, thereby, to improve cardiac function.
G-CSF is a hematopoietic cytokine produced by monocytes, fibroblasts and endothelial cells. G-CSF is known to have multiple functions in normal, steady-state hematopoiesis. It is routinely used to mobilize CD34+ hematopoietic stem cells from the BM into peripheral blood, thus enabling their easier collection compared to BM aspirate procedure. The proven efficacy and safety of G-CSF, both in healthy donors and patients with haematological disease, along with favourable results from studies of CD34+ cell transplantation in patients with MI or ischemia, suggest that G-CSF based BMC transplantation may have an efficacy in patients with MI.
日期
| 最后验证: | 07/31/2018 |
| 首次提交: | 10/21/2013 |
| 提交的预估入学人数: | 10/21/2013 |
| 首次发布: | 10/24/2013 |
| 上次提交的更新: | 08/07/2018 |
| 最近更新发布: | 08/09/2018 |
| 实际学习开始日期: | 09/30/2013 |
| 预计主要完成日期: | 04/30/2018 |
| 预计完成日期: | 04/30/2018 |
状况或疾病
干预/治疗
Drug: G-CSF administration
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Experimental: G-CSF administration Granulocyte Colony-Stimulating Factor (G-CSF) administration - 5 microg/kg subcutaneous every 12 hours for 6 days | Drug: G-CSF administration Zarzio - 5 microg/kg bis in die for 6 days |
| No Intervention: standard therapy Standard therapy |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Patients affected by acute anterior ST elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) or PCI-rescue with persistent occlusion of coronary artery, - Time symptom-to-balloon (≥3 h and ≤12h or ≤24 h if symptoms persist), - Thrombolysis in Myocardial Infarction (TIMI) flow post PCI ≥2, - Evidence of left ventricular (LV) dysfunction (EF biplane ≤45%) ≤24 h after revascularization, - Men and women aged ≥18 years and ≤75 years, - Informed consent must be signed before proceeding with any study procedure. Exclusion Criteria: - Previous anterior MI, - Recent MI (within 1 month), - Known previous LV dysfunction (EF <45%), - Patients with angiographic evidence of coronary anatomy not suitable for PCI, or needing coronary artery bypass grafting (CABG), - Valve disease requiring surgical correction, - History of previous cardiac surgery or PCI on LAD within 6 months, - Previous or current documented history of leukemia, myeloproliferative or myelodysplastic disorder, - Previous or current documented history of malignant disease, - Haemoglobin <10 mg/dl, - White blood cells (WBC) >25.000 mm3, - Platelet <50.000 mm3, - Sepsis, - Known HIV infection, - Immune system diseases, - Interstitial lung disease - Serious concomitant medical conditions (other than ischemic heart disease), - Pregnancy and breast feeding, - Documented alcohol and drug abuse, - Anticipated poor compliance. - Current participation in a clinical trial with other investigational products - Other cell therapy. |
结果
主要结果指标
1. The composite endpoint of: - All cause death or, - recurrence of myocardial infarction (MI) or, - hospitalization due to heart failure. [two years]
次要成果指标
1. - All cause death and cardiovascular events [two years]
其他成果措施
1. Safety endpoints - Incidence and severity of bleeding complications, - incidence of malignancy, - incidence and intensity of serious adverse events (SAEs) and adverse drug reactions (ADRs) [two years]
